Canada recommends lecanemab reimbursement; HSBC raises BIIB to $175
Biogen’s lecanemab received a Canadian public reimbursement recommendation, with follow-on pCPA talks and provincial decisions expected. HSBC increased its price target for Biogen to $175.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.